Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IKT - Inhibikase Therapeutics Inc


IEX Last Trade
1.39
0.003   0.252%

Share volume: 3,098
Last Updated: Fri 30 Aug 2024 08:39:54 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$1.39
0.00
0.25%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
24%
Profitability 25%
Dept financing 6%
Liquidity 75%
Performance 15%
Company vs Stock growth
vs
Performance
5 Days
-2.10%
1 Month
-2.78%
3 Months
-22.65%
6 Months
-36.94%
1 Year
-32.53%
2 Year
-76.90%
Key data
Stock price
$1.39
P/E Ratio 
-0.57
DAY RANGE
N/A - N/A
EPS 
-$2.90
52 WEEK RANGE
$0.79 - $3.82
52 WEEK CHANGE
-$0.29
MARKET CAP 
10.450 M
YIELD 
N/A
SHARES OUTSTANDING 
7.464 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
BETA 
0.57
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$24,966
AVERAGE 30 VOLUME 
$22,422
Company detail
CEO:
Region: US
Website: http://www.inhibikase.com/
Employees: 1
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

inhibikase therapeutics, inc., a clinical stage pharmaceutical company, develops therapeutics for parkinson's disease, and related disorders that arise inside and outside of the brain. the company's product candidates include ikt-148009, a c-abl protein kinase inhibitor for use in the treatment of parkinson's disease, dysphagia, and neurogenic constipation; and ikt-001pro, a prodrug of the anti-cancer agent imatinib that is in preclinical development to minimize gastrointestinal side effects. it offers products comprise ikt-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and ikt-148x series of portfolio compounds for use in the treatment of dementia with lewy body and multiple system atrophy. the company was founded in 2008 and is headquartered in atlanta, georgia.

Recent news